top of page

Hangzhou DAC - Janssen ADC Collaboration

Sexton Riley LLP represented Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, in its June 2022 collaboration and license agreement with Hangzhou DAC Biotechnology Co., Ltd. Under the terms of the agreement, DAC Biotechnology will apply its innovative and proprietary antibody drug conjugate (ADC) platform to Janssen’s proprietary antibodies with the aim to develop novel ADC products against up to five targets. Hangzhou DAC Biotechnology Co., Ltd. is a Chinese high-tech enterprise established in December 2012.


bottom of page